- Home
- EIKN vs ACRS Comparison
EIKN vs ACRS Comparison
Compare EIKN & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EIKN | ACRS |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.6M | 748.6M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | EIKN | ACRS |
|---|---|---|
| Price | $9.22 | $5.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $25.60 | $10.20 |
| AVG Volume (30 Days) | 286.4K | ★ 1.4M |
| Earning Date | 03-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.90 | $1.50 |
| 52 Week High | $16.50 | $5.88 |
Technical Indicators
Market Signals| Indicator | EIKN | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 47.85 |
| Support Level | $8.43 | $4.13 |
| Resistance Level | $13.52 | $5.87 |
| Average True Range (ATR) | 0.73 | 0.31 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 37.57 | 20.69 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.